GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » YoY EPS Growth

Nutra Pharma (Nutra Pharma) YoY EPS Growth : -100.00% (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Nutra Pharma's YoY EPS Growth for the quarter that ended in Sep. 2022 was -100.00%.

Nutra Pharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $0.00.

Nutra Pharma YoY EPS Growth Historical Data

The historical data trend for Nutra Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma YoY EPS Growth Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.00 75.00 - 100.00 -

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 100.00 - -100.00

Nutra Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Nutra Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EPS Growth (A: Dec. 2021 )
=(Earnings per Share (Diluted) (A: Dec. 2021 )-Earnings per Share (Diluted) (A: Dec. 2020 ))/ | Earnings per Share (Diluted) (A: Dec. 2020 ) |
=(-0.002--0)/ | -0 |
=N/A %

Nutra Pharma's YoY EPS Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY EPS Growth (Q: Sep. 2022 )
=(Earnings per Share (Diluted) (Q: Sep. 2022 )-Earnings per Share (Diluted) (Q: Sep. 2021 )) / | Earnings per Share (Diluted) (Q: Sep. 2021 )) |
=(-0-0.001)/ | 0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nutra Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutra Pharma (Nutra Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » YoY EPS Growth
Comparable Companies
SGBI IGPK MJNE PHBI CSTF KAYS VFRM GCAN HCANF CENBF ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 SZSE:000538 VTRS TSE:4507 NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Website
https://www.nutrapharma.com
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired • 04-19-2018